Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Sanofi, UCB Join For Anti-inflammatories

by Rick Mullin
March 17, 2014 | A version of this story appeared in Volume 92, Issue 11

Sanofi and Belgian drugmaker UCB are joining to discover and develop anti-inflammatory small-molecule drugs targeting immune-mediated diseases in areas such as gastroenterology and arthritis. The partners will use a UCB approach for identifying small-molecule modulators of biological pathways for which parenterally administered biologic drugs work well. Sanofi and UCB will share costs and profits on a 50-50 basis. UCB will be entitled to development payments of up to $100 million.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.